Latest News for VCNX
ROCHESTER, N.Y., July 08, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer's disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will present promising new biomarker data from its Phase 1b/2 trial to support plans for an enlarged randomized phase 2B SIGNAL-AD study of pepinemab for treatment…
ROCHESTER, N.Y., April 29, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTCMKTS:VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Alzheimer's, Huntington's disease, and cancer today released financial results for the year ended December 31, 2025. The financial statements have been posted on the company website.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VCNX.
U.S. House Trading
No House trades found for VCNX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.